|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4376110A
(en)
|
1980-08-04 |
1983-03-08 |
Hybritech, Incorporated |
Immunometric assays using monoclonal antibodies
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
DE3572982D1
(en)
|
1984-03-06 |
1989-10-19 |
Takeda Chemical Industries Ltd |
Chemically modified lymphokine and production thereof
|
|
US4945050A
(en)
|
1984-11-13 |
1990-07-31 |
Cornell Research Foundation, Inc. |
Method for transporting substances into living cells and tissues and apparatus therefor
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
CA1310924C
(en)
|
1986-04-24 |
1992-12-01 |
Francis P. Mccormick |
Infective drug delivery system
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4970154A
(en)
|
1987-10-09 |
1990-11-13 |
Baylor College Of Medicine |
Method for inserting foreign genes into cells using pulsed radiofrequency
|
|
EP0315456B1
(en)
|
1987-11-05 |
1994-06-01 |
Hybritech Incorporated |
Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
|
|
US5106627A
(en)
|
1987-11-17 |
1992-04-21 |
Brown University Research Foundation |
Neurological therapy devices
|
|
US4892538A
(en)
|
1987-11-17 |
1990-01-09 |
Brown University Research Foundation |
In vivo delivery of neurotransmitters by implanted, encapsulated cells
|
|
US5158881A
(en)
|
1987-11-17 |
1992-10-27 |
Brown University Research Foundation |
Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
|
|
US5011472A
(en)
|
1988-09-06 |
1991-04-30 |
Brown University Research Foundation |
Implantable delivery system for biological factors
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
CA2006596C
(en)
|
1988-12-22 |
2000-09-05 |
Rika Ishikawa |
Chemically-modified g-csf
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5288855A
(en)
|
1989-01-23 |
1994-02-22 |
Farmitalia Carlo Erba |
Extracellular form of the human fibroblast growth factor receptor
|
|
DK0481000T3
(da)
|
1989-07-06 |
1999-11-15 |
Univ California |
Receptorer for fibroblastvækstfaktorer
|
|
US5676954A
(en)
|
1989-11-03 |
1997-10-14 |
Vanderbilt University |
Method of in vivo delivery of functioning foreign genes
|
|
US5272071A
(en)
|
1989-12-22 |
1993-12-21 |
Applied Research Systems Ars Holding N.V. |
Method for the modification of the expression characteristics of an endogenous gene of a given cell line
|
|
EP1484412A3
(en)
|
1989-12-22 |
2007-10-17 |
Laboratoires Serono SA |
Eukaryotic host cell line in which an endogenous gene has been activated, and uses thereof
|
|
WO1991010470A1
(en)
|
1990-01-08 |
1991-07-25 |
Brown University Research Foundation |
Devices and methods for enhanced delivery of active factors
|
|
ATE356869T1
(de)
|
1990-01-12 |
2007-04-15 |
Amgen Fremont Inc |
Bildung von xenogenen antikörpern
|
|
US5672510A
(en)
|
1990-01-19 |
1997-09-30 |
Genetic Therapy, Inc. |
Retroviral vectors
|
|
AU662107B2
(en)
|
1990-07-06 |
1995-08-24 |
Aventis Pharmaceuticals Inc. |
Fibroblast growth factor receptors
|
|
CA2089661C
(en)
|
1990-08-29 |
2007-04-03 |
Nils Lonberg |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5217889A
(en)
|
1990-10-19 |
1993-06-08 |
Roninson Igor B |
Methods and applications for efficient genetic suppressor elements
|
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
|
US5229501A
(en)
|
1991-01-11 |
1993-07-20 |
Chiron Corporation |
Expression and use of human fibroblast growth factor receptor
|
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
|
IL100219A0
(en)
|
1991-12-02 |
1992-09-06 |
Yeda Res & Dev |
Variable region within fibroblast growth factor receptors that confers ligand specificity
|
|
WO1993015722A1
(en)
|
1992-02-07 |
1993-08-19 |
Syntex (Usa) Inc. |
Controlled delivery of pharmaceuticals from preformed porous microparticles
|
|
US5234784A
(en)
|
1992-04-01 |
1993-08-10 |
Eastman Kodak Company |
Method of making a projection viewable transparency comprising an electrostatographic toner image
|
|
US5364791A
(en)
|
1992-05-14 |
1994-11-15 |
Elisabetta Vegeto |
Progesterone receptor having C. terminal hormone binding domain truncations
|
|
DK0646182T3
(da)
|
1992-06-18 |
1996-09-16 |
Whittier Inst Diabetes & Endoc |
Fremgangsmåde til påvisning af neoplastiske sygdomme
|
|
SG48760A1
(en)
|
1992-07-24 |
2003-03-18 |
Abgenix Inc |
Generation of xenogenetic antibodies
|
|
US5474914A
(en)
|
1992-07-29 |
1995-12-12 |
Chiron Corporation |
Method of producing secreted CMV glycoprotein H
|
|
US5489743A
(en)
|
1993-01-19 |
1996-02-06 |
Amgen Inc. |
Transgenic animal models for thrombocytopenia
|
|
US5581476A
(en)
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
|
GB9313210D0
(en)
*
|
1993-06-25 |
1993-08-11 |
Sandoz Ltd |
Novel combinations
|
|
US6664107B1
(en)
|
1993-05-26 |
2003-12-16 |
Ontario Cancer Institute, University Health Network |
CD45 disrupted nucleic acid
|
|
WO1994028122A1
(en)
|
1993-05-26 |
1994-12-08 |
Ontario Cancer Institute |
Transgenic mammals lacking expression of particular cd45 isoforms
|
|
US5589362A
(en)
|
1993-06-14 |
1996-12-31 |
Basf Aktiengesellschaft |
Tetracycline regulated transcriptional modulators with altered DNA binding specificities
|
|
ES2140359T1
(es)
|
1993-06-14 |
2000-03-01 |
Basf Ag |
Control preciso de expresion genetica en celulas eucarioticas mediante promotores que responden a la tetaciclina.
|
|
US5654168A
(en)
|
1994-07-01 |
1997-08-05 |
Basf Aktiengesellschaft |
Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units
|
|
US5469743A
(en)
*
|
1993-06-24 |
1995-11-28 |
Zorn; Roger H. |
Dynamic surface wave roll inspection device
|
|
DE69430824T2
(de)
|
1993-08-12 |
2003-01-23 |
Neurotech S.A., Evry |
Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
US5824784A
(en)
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
|
US5654166A
(en)
*
|
1994-11-09 |
1997-08-05 |
Kurth; Gerhard P. |
Process of preparing hormone-free bovine cartilage for dosage form
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
ATE390933T1
(de)
|
1995-04-27 |
2008-04-15 |
Amgen Fremont Inc |
Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
|
|
WO1996037609A1
(en)
|
1995-05-26 |
1996-11-28 |
Zeneca Limited |
A gene switch comprising an ecdysone receptor
|
|
WO1996040958A1
(en)
|
1995-06-07 |
1996-12-19 |
Baylor College Of Medicine |
Nucleic acid transporters for delivery of nucleic acids into a cell
|
|
US5849303A
(en)
|
1995-06-07 |
1998-12-15 |
American Home Products Corporation |
Recombinant feline Immunodeficiency virus subunit vaccines employing baculoviral-expressed envelope glycoproteins derived from isolate NCSU-1 and their use against feline immunodeficiency virus infection
|
|
CA2219080A1
(en)
|
1995-06-07 |
1996-12-27 |
Ariad Gene Therapeutics, Inc. |
Rapamycin-based regulation of biological events
|
|
CA2244363C
(en)
|
1996-02-28 |
2006-11-14 |
Ariad Gene Therapeutics, Inc. |
Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5679559A
(en)
|
1996-07-03 |
1997-10-21 |
University Of Utah Research Foundation |
Cationic polymer and lipoprotein-containing system for gene delivery
|
|
US6214795B1
(en)
|
1996-11-12 |
2001-04-10 |
Praecis Pharmaceuticals, Inc. |
Peptide compounds useful for modulating FGF receptor activity
|
|
JP4112627B2
(ja)
|
1996-12-26 |
2008-07-02 |
社団法人芝蘭会 |
新規ポリペプチド、新規ｄｎａおよび新規抗体
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
EP0861900A1
(en)
*
|
1997-02-21 |
1998-09-02 |
Erziehungsdirektion Of The Canton Zurich |
Immunological detection of prions
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
US6150096A
(en)
*
|
1997-09-26 |
2000-11-21 |
Universite De Sherbrooke |
Molecular markers for the diagnosis of human diseases including Crohn's disease
|
|
AU733222B2
(en)
|
1997-11-25 |
2001-05-10 |
Genentech Inc. |
Fibroblast growth factor-19
|
|
US6150098A
(en)
|
1998-02-20 |
2000-11-21 |
Amgen Inc. |
Methods for identifying novel secreted mammalian polypeptides
|
|
ZA200007412B
(en)
|
1998-05-15 |
2002-03-12 |
Imclone Systems Inc |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
WO2000027885A1
(en)
|
1998-11-05 |
2000-05-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Novel chimeric polypeptide
|
|
US6656728B1
(en)
|
1999-02-08 |
2003-12-02 |
Chiron Corporation |
Fibroblast growth factor receptor-immunoglobulin fusion
|
|
AU3755900A
(en)
|
1999-03-15 |
2000-10-04 |
Chiron Corporation |
Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
|
|
CA2311201A1
(en)
|
1999-08-05 |
2001-02-05 |
Genset S.A. |
Ests and encoded human proteins
|
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
AU7368100A
(en)
|
1999-09-10 |
2001-04-10 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
|
WO2001032678A1
(en)
|
1999-11-05 |
2001-05-10 |
Smithkline Beecham Corporation |
sbgFGF-19a
|
|
EP1232264B1
(en)
*
|
1999-11-18 |
2009-10-21 |
Novartis Vaccines and Diagnostics, Inc. |
Human fgf-21 gene and gene expression products
|
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
|
AU1628101A
(en)
|
1999-11-22 |
2001-06-04 |
Millennium Pharmaceuticals, Inc. |
Jaffa, a novel fibroblast growth factor family member and uses therefor
|
|
US7108984B2
(en)
|
2000-01-12 |
2006-09-19 |
Mount Sinai School Of Medicine |
Methods of identifying modulators of the FGF receptor
|
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
|
WO2001049849A1
(en)
|
2000-01-05 |
2001-07-12 |
Zymogenetics, Inc. |
Novel fgf homolog zfgf11
|
|
AU5056501A
(en)
|
2000-03-31 |
2001-10-08 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
|
JP2002112772A
(ja)
|
2000-07-10 |
2002-04-16 |
Takeda Chem Ind Ltd |
新規ポリペプチドおよびそのｄｎａ
|
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
|
US20030157561A1
(en)
|
2001-11-19 |
2003-08-21 |
Kolkman Joost A. |
Combinatorial libraries of monomer domains
|
|
US20060223114A1
(en)
|
2001-04-26 |
2006-10-05 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
|
US20040018499A1
(en)
|
2001-06-06 |
2004-01-29 |
Lal Preeti G |
Extracellular messengers
|
|
JP2005500034A
(ja)
|
2001-06-20 |
2005-01-06 |
プロション バイオテク リミテッド |
受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
|
|
WO2003006501A2
(en)
|
2001-07-11 |
2003-01-23 |
Maxygen Holdings, Ltd. |
G-csf conjugates
|
|
AU2002322394A1
(en)
|
2001-07-30 |
2003-02-17 |
Eli Lilly And Company |
Method for treating diabetes and obesity
|
|
WO2003038054A2
(en)
|
2001-10-31 |
2003-05-08 |
New York University |
Structure-based design and synthesis of fgf inhibitors and fgf modulator compounds
|
|
WO2003059270A2
(en)
|
2002-01-15 |
2003-07-24 |
Eli Lilly And Company |
Method for reducing morbidity and mortality in critically ill patients
|
|
WO2003063893A2
(en)
|
2002-01-31 |
2003-08-07 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Fgfr agonists
|
|
EP1332761A1
(en)
|
2002-01-31 |
2003-08-06 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Agonists of fibroblast growth factor receptors (FGFR)
|
|
IL149562A0
(en)
|
2002-05-09 |
2002-11-10 |
Prochon Ltd |
Fgf variants and methods for use thereof
|
|
JP2003334088A
(ja)
|
2002-05-22 |
2003-11-25 |
Pharma Design Inc |
ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
|
|
AU2003265057A1
(en)
|
2002-09-04 |
2004-03-29 |
Abtech |
Anti-idiotypic antibodies as vegf or fgf agonists for bone therapy
|
|
JP2006515747A
(ja)
|
2002-11-01 |
2006-06-08 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
|
JP2007524566A
(ja)
|
2002-12-20 |
2007-08-30 |
エンカム ファーマシューティカルズ アクティーゼルスカブ |
レセプターとリガンドの間の相互作用の調節の方法
|
|
TWI300430B
(en)
*
|
2003-01-10 |
2008-09-01 |
Ritek Corp |
Optical recording medium dye and optical recording medium using thereof
|
|
CA2487406C
(en)
*
|
2003-01-23 |
2012-02-21 |
Lg Electronics Inc. |
Recording medium with copy protection information formed in intermittent or alternate wobbled pits and apparatus and methods for forming, recording, and reproducing the recording medium
|
|
WO2004083381A2
(en)
|
2003-03-13 |
2004-09-30 |
Indiana University Advanced Research & Technology Institute |
Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants
|
|
JP2006240990A
(ja)
|
2003-05-15 |
2006-09-14 |
Kirin Brewery Co Ltd |
ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
|
|
US20070253966A1
(en)
|
2003-06-12 |
2007-11-01 |
Eli Lilly And Company |
Fusion Proteins
|
|
AU2004251145C1
(en)
|
2003-06-12 |
2011-04-14 |
Eli Lilly And Company |
GLP-1 analog fusion proteins
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
EP1680140B1
(en)
|
2003-10-16 |
2011-04-20 |
Imclone LLC |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
BRPI0416683A
(pt)
|
2003-12-10 |
2007-01-30 |
Lilly Co Eli |
muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
|
|
CA2550245A1
(en)
|
2003-12-19 |
2005-07-21 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
WO2005072769A1
(en)
|
2004-01-26 |
2005-08-11 |
Eli Lilly And Company |
Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
|
|
US7887790B2
(en)
*
|
2004-02-20 |
2011-02-15 |
Cornell Research Foundation, Inc. |
Polymers and polymer coatings
|
|
JP2007531715A
(ja)
|
2004-03-17 |
2007-11-08 |
イーライ リリー アンド カンパニー |
グリコール結合ｆｇｆ−２１化合物
|
|
JP4505631B2
(ja)
|
2004-03-31 |
2010-07-21 |
独立行政法人産業技術総合研究所 |
ヘパラン硫酸糖鎖を付加したヘパリン結合性タンパク質、その製造方法及びそれを含有する医薬組成物
|
|
EP2194064A1
(en)
|
2004-05-13 |
2010-06-09 |
Eli Lilly & Company |
FGF-21 fusion proteins
|
|
BRPI0514790A
(pt)
|
2004-09-02 |
2008-06-24 |
Lilly Co Eli |
muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
|
|
EP1789443A1
(en)
|
2004-09-02 |
2007-05-30 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
DK2586456T3
(en)
|
2004-10-29 |
2016-03-21 |
Ratiopharm Gmbh |
Conversion and glycopegylation of fibroblast growth factor (FGF)
|
|
JP2008522617A
(ja)
*
|
2004-12-14 |
2008-07-03 |
イーライ リリー アンド カンパニー |
線維芽細胞成長因子２１の突然変異タンパク質
|
|
US20080261875A1
(en)
|
2005-01-21 |
2008-10-23 |
Eli Lilly And Company |
Method For Treating Cardiovascular Disease
|
|
JP2006246823A
(ja)
|
2005-03-11 |
2006-09-21 |
Kyoto Univ |
造血因子としてのＦｇｆ２１の使用
|
|
WO2006130527A2
(en)
|
2005-05-31 |
2006-12-07 |
Novartis Ag |
Mutations and polymorphisms of fibroblast growth factor receptor 1
|
|
EP1910542B1
(en)
|
2005-07-22 |
2009-12-02 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with fgfr fusion proteins
|
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
US7395962B2
(en)
|
2005-10-28 |
2008-07-08 |
United Parcel Service Of America, Inc. |
Pick up notice and method of using same
|
|
WO2007055789A2
(en)
|
2005-10-31 |
2007-05-18 |
Neose Technologies, Inc. |
Expression of soluble therapeutic proteins
|
|
EP1996215A2
(en)
|
2006-02-28 |
2008-12-03 |
Trustees Of Boston University |
Metabolic regulators and uses thereof
|
|
WO2007144893A2
(en)
|
2006-06-15 |
2007-12-21 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
CN101516388B
(zh)
|
2006-07-21 |
2012-10-31 |
诺和诺德公司 |
通过o-联糖基化序列的肽的糖基化
|
|
EP2054521A4
(en)
|
2006-10-03 |
2012-12-19 |
Novo Nordisk As |
PROCESS FOR CLEANING POLYPEPTIDE CONJUGATES
|
|
JP2010511382A
(ja)
|
2006-12-01 |
2010-04-15 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
癌関連タンパク質キナーゼ
|
|
KR20140012199A
(ko)
|
2007-03-30 |
2014-01-29 |
암브룩스, 인코포레이티드 |
변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
|
|
SI2550972T1
(en)
|
2007-04-02 |
2018-05-31 |
Genentech, Inc. |
An antibody called Klotho-beta agonist for use in the treatment of diabetes mellitus or insulin resistance
|
|
JP5187837B2
(ja)
|
2007-04-06 |
2013-04-24 |
独立行政法人産業技術総合研究所 |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
|
US7537903B2
(en)
|
2007-04-23 |
2009-05-26 |
Board Of Regents, The University Of Texas System |
FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
|
|
WO2008135993A1
(en)
|
2007-05-08 |
2008-11-13 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
|
JP2010529954A
(ja)
|
2007-05-22 |
2010-09-02 |
ノバルティス アーゲー |
Ｆｇｆ２１関連障害を処置、診断および検出する方法
|
|
US8481497B2
(en)
|
2007-05-29 |
2013-07-09 |
Sapporo Medical University |
Therapeutic agent for cancer, and method for treatment of cancer
|
|
CN101778937A
(zh)
|
2007-06-04 |
2010-07-14 |
诺和诺德公司 |
使用n-乙酰葡糖胺转移酶的o-联糖基化
|
|
WO2009020802A2
(en)
|
2007-08-03 |
2009-02-12 |
Eli Lilly And Company |
Treatment for obesity
|
|
WO2009020602A2
(en)
|
2007-08-08 |
2009-02-12 |
Foster-Miller, Inc. |
Watercraft drogue system
|
|
US8426396B2
(en)
|
2008-01-08 |
2013-04-23 |
Shriners Hospitals For Children |
Treatment for achondroplasia
|
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
|
WO2009117622A2
(en)
|
2008-03-19 |
2009-09-24 |
Ambrx, Inc. |
Modified fgf-23 polypeptides and their uses
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
BRPI0916904A2
(pt)
|
2008-08-04 |
2016-10-11 |
Fiveprime Therapeutics Inc |
polipeptídeos, moléculares de fusão ecd fgfr4, composições farmacêuticas, polinucleotídio e métodos de tratamento de desordem angiogênica, câncer em paciente e degeneração macular em paciente e respectivos usos
|
|
MX2011011815A
(es)
|
2009-05-05 |
2012-01-27 |
Amgen Inc |
Mutantes fgf21 y usos de los mismos.
|
|
PT3248610T
(pt)
|
2009-05-05 |
2024-02-01 |
Amgen Inc |
Mutantes fgf21 e suas utilizações
|